1 / 13

altaweb.it/hepacivac

www.altaweb.it/hepacivac. The HCV vaccine: cooperation in the shadow of the pyramids. Antonella Folgori. Estimated 170 Million Persons With HCV Infection Worldwide. 3-4 million newly infected each year worldwide. Europe 8.9 million. Western Pacific 62.2 million. Americas 13.1 million.

janellep
Download Presentation

altaweb.it/hepacivac

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. www.altaweb.it/hepacivac The HCV vaccine: cooperation in the shadow of the pyramids Antonella Folgori

  2. Estimated 170 Million Persons With HCV Infection Worldwide • 3-4 million newly infected each year worldwide Europe 8.9 million Western Pacific 62.2 million Americas 13.1 million Southeast Asia 32.3 million Eastern Mediterranean 21.3 million Africa 31.9 million Prevalence of infection >10% 2.5%–10% 0.5%–2.5% No information World Health Organization 2008

  3. Egypt has the highest prevalence of HCV infection in the world • 15% anti-HCV positive among adult rural Nile Delta inhabitants (EDHS, 2009; Strickland 2006; Frank et al, 2000; Abdel-Aziz et al, 2000; Waked et al, 1995) Europe 8.9 million Western Pacific 62.2 million Americas 13.1 million Southeast Asia 32.3 million Eastern Mediterranean 21.3 million Africa 31.9 million Prevalence of infection >10% 2.5%–10% 0.5%–2.5% No information

  4. HCV infection and medical needs • Infection is usually asymptomatic • 80% of infected individuals become chronic • HCV is a common cause of liver disease and represents a major threat to the health of many people around the world • Interferon based treatment is effective in many people but it has extensive side effects and it is very expensive • The addition of new antiviral agents will improve virological response rates and decrease the duration of treatment but will likely have further side effects and additional costs • Large population of undiagnosed and untreated persons • Historically, vaccination is needed to eradicate infectious diseases - not drugs 19

  5. A new vaccination approach • A classical vaccine triggers the production of antibodies which recognize the surface of the virus • In the case of HCV this structural part changes constantly Target cell Virus Antibodies • The new vaccination approach relies on the generation of «killer» T lymphocytes that reacts to the presence of infectious agents and destroy the infected cells • In the case of HCV T-cell response plays a critical role in viral control in early infection Virus Infected target cell Cytotoxic T lymphocytes

  6. Antigenic peptide Antigen MHC Genetic vaccines • The best way to elicit a T cell response is to deliver the gene coding for parts of the infectious agents • The gene is used as a source of antigen and the muscle as a “bioreactor” to produce the corresponding protein Immune system activation (T cells & Abs) Recombinant viral vectors Antigen encoding gene

  7. HCV vaccine: an international team of researchers is rising to the challenge • 12 project partners from 7 countries: Belgium, Germany, Italy, the Netherlands, Poland, UK and Egypt • Development of a prophylactic HCV vaccine – to eradicate infection • Use the same approach to treat infected patients – to improve on SOC

  8. HCV Vaccine for Prophylaxys and Therapy: The HEPACIVAC Strategy Surface antigens Non Structural antigens HCV E1E2 NS Subunit vaccine Genetic vaccine 1 +++ Antibodies +/- T cells +++ T cells Genetic vaccine 2 NO GO Preclinical evaluation in mice and non human primates Go to Clinical trials Manufacturing in GMP 01

  9. Has the effort been successful? • Whatnext? 06

  10. Achievements - I • Preclinical testing of the vaccine: safety, tolerability and strong immunogenicity demonstrated in animal models • Standardization of the procedures for pre-clinical and clinical trials for HCV • Transfer of knowledge (and reagents!) between participant groups in particular from Europe to Egypt • Evaluation of HCV incidence and cell mediated immune responses among Egyptian HCW: a preparedness study for a future Phase II trial of the HCV prophylactic vaccine in Egypt

  11. Achievements - II • Two Clinical studies in healthy volunteers for safety, dose and administration regimens optimization – completed: vaccine very safe & highly immunogenic • Three Clinical studies in in chronically infected patients with and without the gold standard therapy – in progress; interim data showed that the vaccine is safe and immunogenic Post-HEPACIVAC plans: translate the results into effective approaches for prevention and therapy of HCV • Phase II efficacy study of the HEPACIVAC vaccine in high risk individuals • Established strategic alliance with UCSF and JH in the US who study target populations with high and stable incidence of HCV infection • Support from NIH • Clinical studies in Egypt

  12. Collaborative research required: • Tight coordination • Networking • Exchange of experimental data and discussion / teleconference meetings among «working groups» • Supervision of the activities so as to ensure the progression of the project towards the delivery of the objectives • Open discussion during annual meetings Cairo, 2009

  13. Acknowledgments:

More Related